In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics, with a price target of $24.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Capricor Therapeutics’ upcoming pivotal data release and the potential regulatory flexibility from the FDA. The imminent data from the HOPE-3 trial is a significant catalyst, and while there is anticipation around the primary endpoint of PUL 2.0, there is also an expectation of potential volatility in CAPR’s stock as investors react to the news. Pantginis highlights the possibility of regulatory flexibility if the primary endpoint is not met, particularly if the LVEF signal is strong, which could still support a positive outlook for the stock.
Furthermore, Pantginis maintains a positive stance on the potential impact of deramiocel in treating Duchenne Muscular Dystrophy (DMD), supported by strong historical data from the HOPE-2 trial. The durability of the clinical data, showing significant improvements in PUL and LVEF assessments over four years, reinforces the belief in the therapeutic’s efficacy. Despite the uncertainties and regulatory challenges, Pantginis remains optimistic about Capricor’s prospects, underpinned by the promising clinical outcomes and the potential for regulatory approval.
According to TipRanks, Pantginis is a 3-star analyst with an average return of 2.2% and a 44.09% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Esperion, and Travere Therapeutics.